ArticleTranslational cancer research2026
Predictive value of HALP score for clinical outcomes in lung cancer patients: a systematic review and meta-analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hemoglobin-albumin-lymphocyte-platelet (HALP) index has emerged as a composite indicator reflecting nutritional and inflammatory status. Its prognostic relevance in lung cancer remains inconsistent across studies. This study quantitatively evaluated the association between pretreatment HALP levels and clinical outcomes in lung cancer. Methods: Several electronic databases were searched up to April 7, 2025. Primary endpoints included overall survival (OS) and progression-free survival (PFS). Secondary endpoints consisted of disease control rate (DCR), objective response rate (ORR), 90-day mortality, and cachexia. Hazard ratios (HRs) and odds ratios (ORs) were combined for the primary and secondary outcomes, respectively. Subgroup analyses based on tumor type and treatment were performed. Results: Sixteen studies were enrolled. Pooled results indicated that lower HALP score significantly predicted worse OS [HR =0.60; 95% confidence interval (CI): 0.50-0.73; P<0.001] and PFS (HR =0.52; 95% CI: 0.39-0.69; P<0.001). Subgroup analysis manifested similar results. For the secondary outcomes, pretreatment HALP score was also related to 90-day mortality (OR =0.35; 95% CI: 0.24-0.51; P<0.001) and cachexia (OR =0.76; 95% CI: 0.61-0.95; P=0.02). However, non-significant association of pretreatment HALP score with DCR (OR =1.85; P=0.06) or ORR (OR =1.01; P=0.96) was observed. Conclusions: Pretreatment HALP score might serve as a novel predictor for clinical outcomes in lung cancer and a lower HALP score predicts worse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.